Skip to main content
Pharmaron Beijing Co., Ltd. logo

Pharmaron Beijing Co., Ltd. — Investor Relations & Filings

Ticker · 300759 ISIN · CNE100003JW4 LEI · 300300JYXHGVS5SNGG54 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,323 across all filing types
Latest filing 2025-09-04 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 300759

About Pharmaron Beijing Co., Ltd.

https://www.pharmaron.cn

Pharmaron Beijing Co., Ltd. is a premier R&D service provider for the life sciences industry, offering a comprehensive, fully integrated platform for drug discovery, development, and manufacturing. The company supports global pharmaceutical and biotechnology partners through a wide range of services, including laboratory chemistry, biology, DMPK, pharmacology, and safety assessment. Its capabilities extend to clinical development services and commercial-scale manufacturing for small molecules, biologics, and cell and gene therapies. By leveraging advanced technology and a global network of facilities, the company facilitates the transition of drug candidates from initial concept to market approval, optimizing the efficiency and success of the drug development lifecycle.

Recent filings

Filing Released Lang Actions
关于持股5%以上股东减持计划实施完成的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the completion of a shareholding reduction plan by a shareholder holding more than 5% of the company's shares. It details the number of shares reduced, the methods of reduction, the period, prices, and the shareholder's holdings before and after the reduction. It references compliance with regulatory rules on shareholding reduction and confirms no change in control or adverse impact on governance. There are no financial statements or detailed financial performance data, nor is this a report or presentation. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2025-09-04 Chinese
H股公告
Regulatory Filings Classification · 95% confidence The document is a monthly securities movement report for a listed company, detailing changes in registered capital, issued shares, treasury shares, and stock incentive plans. It references compliance with Hong Kong Stock Exchange Listing Rules Chapter 19B and includes detailed tables of share capital and share movements for the month ending August 31, 2025. The document is a regulatory disclosure about share capital changes and stock incentive plans, not a financial report, earnings release, or management discussion. It is not an announcement of voting results or a proxy statement. The document is a regulatory filing related to share capital and securities movements under listing rules, fitting the category of Regulatory Filings (RNS). The document length is 4256 characters, which is substantive and contains detailed data, not just a brief announcement or certification. Therefore, the best classification is Regulatory Filings (RNS).
2025-09-04 Chinese
2025年半年度非经营性资金占用及其他关联资金往来情况汇总表
Interim / Quarterly Report Classification · 85% confidence The document is a detailed tabular summary of non-operating fund occupation and other related party fund transactions for the half-year period of 2025. It includes specific financial figures such as beginning balances, cumulative amounts, interest, repayments, and ending balances for various related parties and subsidiaries. The content is focused on financial data for a half-year period and involves substantive financial information rather than just an announcement or summary. The document length is 2360 characters, which is relatively short, but the content is detailed financial data rather than a simple announcement or certification. Given the half-year period and the detailed financial data, this fits the definition of an Interim / Quarterly Report (IR).
2025-08-21 Chinese
第三届监事会第十三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 13th meeting of the third Supervisory Board of Kanglong Huacheng (Beijing) New Drug Technology Co., Ltd. It includes voting results and approvals related to the 2025 semi-annual report, investment decisions, and stock incentive plans. The document references the approval of the 2025 semi-annual report and related announcements but does not contain the actual financial statements or detailed financial data itself. The length is 4280 characters, which is relatively short and consistent with an announcement rather than a full report. The document serves as a formal disclosure of meeting resolutions and approvals rather than the report itself. Therefore, it fits best into the category of Regulatory Filings (RNS), which is the fallback for such announcements that do not contain full financial reports or detailed data.
2025-08-21 Chinese
第三届董事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 15th meeting of the third board of directors of Kanglong Huacheng (Beijing) New Drug Technology Co., Ltd. It includes approvals of the 2025 semi-annual report and related disclosures, investment decisions, adjustments to stock incentive plans, and governance policy updates. The document contains voting results and references to other detailed announcements and reports published elsewhere. The content focuses on board meeting decisions and governance matters rather than the full financial report itself. The document length is about 4,824 characters, which is substantial but the content is clearly a board meeting resolution announcement. Therefore, the most appropriate classification is Board/Management Information (MANG).
2025-08-21 Chinese
上海妙道企业管理咨询有限公司关于公司2022年A股限制性股票激励计划第三个归属期归属条件成就相关事项之独立财务顾问报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" related to the 2022 A-share restricted stock incentive plan of Kanglong Huacheng (Beijing) New Drug Technology Co., Ltd. It discusses the achievement of vesting conditions for the third vesting period of the restricted stock incentive plan, including detailed approval procedures, performance conditions, and the number of shares eligible for vesting. The document is a detailed advisory report prepared by an independent financial advisor, providing an opinion on the stock incentive plan's vesting conditions and compliance with relevant laws and regulations. It is not a general annual or interim financial report, nor is it a simple announcement or voting result. It is a standalone advisory report related to a specific financial incentive plan and its conditions. This fits best under the category of Audit Report / Information (AR), which includes standalone audit or advisory reports related to accounting, financial conditions, or regulatory compliance, excluding full annual reports. The document length (9414 characters) and content confirm it is a full report, not just an announcement or certification. Therefore, the classification is AR with high confidence.
2025-08-21 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.